GeneTex
United States (US)

PKC mu (Active) recombinant protein

Cat No. GTX65216

Application ELISA, Functional Assay, Apuri, Blocking
Reactivity Human
Species Human
APPLICATION

Application Note

680 nmol phosphate incorporated into CREBTIDE substrate peptide per minute per mg protein at 30ºC for 15 minutes using a final concentration of 50 uM ATP (0.83 uCi/assay).

Calculated MW

131.0 kDa. ( Note )
PROPERTIES

Form

Liquid

Buffer

50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.25 mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, 25% glycerol

Storage

Store at -80ºC. Product is stable for at least 6-12 months.

Concentration

0.1mg/ml(Please refer to the vial label for the specific concentration.)

Antigen Species

Human

Expression System

Baculovirus (Sf9 insect cells)

Purification


Purity was assessed by SDS-PAGE (≥90%) and by HPLC.

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

Protein Kinase D1,Chded,Pkc-Mu,Pkcm,Pkd,Prkcm,Prkd1

Background

Protein kinase Cmu (PKCmu) is a novel member of the protein kinase C (PKC) family that differs from the other isoenzymes in structural and enzymatic properties. It is characterized by the presence of a pleckstrin homology (PH) domain and an amino-terminal hydrophobic region and has substrate specificity distinct from other PKC isoforms. PKCmu is a ubiquitous PKC isotype with the highest expression in the thymus, lung and peripheral blood mononuclear cells (1). PKCmu forms a complex in vivo with a phosphatidylinositol 4-kinase and a phosphatidylinositol-4-phosphate 5-kinase. A region of PKCmu between the amino-terminal transmembrane domain and the pleckstrin homology domain is shown to be involved in the association with the lipid kinases (2). PKCmu was also shown to associate with the B cell receptor (BCR) complex and its activity is up-regulated after cross-linking the BCR and CD19 on B cells (3). PKC mu co-precipitates with Syk and phospholipase C-gamma 1/2 (PLC gamma 1/2) and in vitro phosphorylation of fusion proteins showed that both Syk and PLC gamma 1 are potential substrates of PKC mu in vivo. In addition, specific interaction of PKCmu and 14-3-3tau can be shown in the T cell line Jurkat by immunocoprecipitiation and by pulldown assays (4). 14-3-3tau is not a substrate of PKCmu and strongly down-regulates PKCmu kinase activity in vitro. In response to various stimuli, PKC mu activates the mitogen-activated protein kinase (p42/ERK1 MAPK cascade) but does not affect the related c-jun N-terminal kinase or p38 MAPK (5).

Research Area